

Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2023)	Global Fund ERP recommended	GDF Catalog	Status
												<ul style="list-style-type: none"> ■ Yes ■ No ■ Ineligible for inclusion ■ N/A
Ethambutol 50mg dispersible tablet	Yes	Yes	No	No	No	N/A	Yes	No	No	Ineligible for inclusion	Ineligible for inclusion	
Ethambutol 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Ethambutol 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	Yes	
Ethionamide 125mg dispersible tablet	N/A	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 50mg dispersible tablet	Yes	Yes	No	No	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	No	
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: August 2023

Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2023)	Global Fund ERP recommended	GDF Catalog	Status
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Pyrazinamide 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Rifampicin 20mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	No	No
Rifampicin/Isoniazid 75/50 dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Rifampicin/Isoniazid/Pyrazinamide 75/50/150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: August 2023